Biography

Sarah counsels hospitals, universities, research institutions, and biotech, pharmaceutical, diagnostic, and device companies on a range of regulatory, compliance, and transactional matters.

She regularly assists life sciences and academic clients in connection with sponsored, investigator initiated, and collaborative research studies including structuring of research arrangements, drafting and negotiating of contract research organization and clinical trial agreements, drafting of informed consent and HIPAA authorization documents, and advising in connection with FDA regulatory requirements for clinical investigations, secondary use of data and biospecimens, subject injury, and clinical trial reimbursement.

Hospital clients turn to Sarah to provide guidance on accountable care organization formation and structuring relationships with providers. Sarah also has experience advising on controlled substance matters, pharmacy matters, and the 340B program.

Sarah's practice also includes assisting clients on compliance with state and federal privacy laws, fraud and abuse laws, and professional and facility licensure requirements.

Before joining Verrill, Sarah worked in the health care group at Ropes & Gray LLP for 11 years, most recently as Senior Attorney.

Services/Industries

Education

  • Vanderbilt University Law School  (J.D., Order of the Coif)
  • Tufts University  (B.A., summa cum laude)

Public Service

  • Community Member, Judge Baker Children's Center Institutional Review Board (2010-2014)

Bar Admissions

  • Massachusetts

Firm Highlights

Publication/Podcast

FDA Updates its Guidance on Conducting Clinical Trials During COVID-19 Public Health Emergency

On April 16, 2020, the U.S. Food & Drug Administration (“FDA”) again updated its guidance on the “Conduct of Clinical Trials of Medical Products during COVID-19 Public Health Emergency,” adding seven new questions and...

Publication/Podcast

COVID-19: FDA Clinical Trial Guidance

On March 18, 2020, the U.S. Food & Drug Administration (“FDA”) published guidance for clinical trial sponsors, investigators, and institutional review boards (“IRBs”) on conducting clinical trials in the midst of the COVID-19 pandemic...

Publication/Podcast

Two Proposed Rules Aim to Increase Organ Donation in the U.S.

Publication/Podcast

Updated FDA COVID-19 Guidance for Conduct of Clinical Trials

On March 27, 2020, the U.S. Food & Drug Administration (“FDA”) updated its prior guidance on the “ Conduct of Clinical Trials of Medical Products during COVID-19 Pandemic ,” with an appendix adding a...

Publication/Podcast

FDA Announces New Updates to its Guidance on Conducting Clinical Trials During COVID-19 and Notes Availability of its COVID MyStudies App

On June 3, 2020, the U.S. Food & Drug Administration (“FDA”) again updated its guidance on the “ Conduct of Clinical Trials of Medical Products during COVID-19 Public Health Emergency ” with new information...

Publication/Podcast

OHRP Issues Guidance on the Conduct of Research During COVID-19 Public Health Emergency

The U.S. Department of Health & Human Services Office for Human Research Protections (“OHRP”) issued guidance , dated April 8, 2020, on the application of Common Rule requirements to research being conducted during the...

Publication/Podcast

Due to COVID-19, Federal Agencies Relax Requirements Regarding the Provision of Telehealth Services

In the past few days, in an effort to help keep Medicare beneficiaries healthy during the COVID-19 pandemic, key federal agencies within the U.S. Department of Health and Human Services (“HHS”) and the U.S...